SOLV Stock Recent News

Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimated at $5.50-$6.00 and leverage much lower post-divestment.

ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close.

Investors need to pay close attention to SOLV stock based on the movements in the options market lately.

Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's  three-phased Transformation Plan ST. PAUL, Minn.

ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m.

Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.

Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.

Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Frederick Wise - Stifel, Nicolaus & Company, Inc. Jason Bednar - Piper Sandler & Co. David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Steven Valiquette - Mizuho Securities Operator Good afternoon. My name is Amy [ph] and I will be your conference call operator for today.

Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price.

SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.